Skip to main content
. 2017 Jul 2;73(10):1247–1252. doi: 10.1007/s00228-017-2292-5

Fig. 4.

Fig. 4

Knowledge testing. Q12: What may be the consequence of a PGx polymorphism? Q13: The EMA currently includes PGx information in the drug labels of how many medications? Q14: What does a PM phenotype indicate? Q15: A person who is a PM for CYP2D6 gets a medication that induces CYP2D6. What may be a consequence?